Analysis of Antibody-Drug Conjugate Target Expression Across Genomic Subsets of Non-Small Cell Lung Cancer

被引：0
|
作者：
Lin, J. J. [1 ]
Yeap, B. Y. [1 ]
Peterson, J. L. [1 ]
Do, A. [1 ]
Banwait, M. K. [1 ]
Schwartz, J. [1 ]
Ganci, M. L. [1 ]
Hata, A. N. [1 ]
Heist, R. S. [1 ]
Piotrowska, Z. [1 ]
Gainor, J. F. [1 ]
Mino-Kenudson, M. [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Antibody-drug conjugate; Protein expression; Resistance;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.06B.06
引用
收藏
页码：S167 / S168
页数：2
相关论文
共 50 条
  • [1] The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
    Liu, Xinlin
    Deng, Junwen
    Zhang, Renshuai
    Xing, Jiyao
    Wu, Yudong
    Chen, Wujun
    Liang, Bing
    Xing, Dongming
    Xu, Jiazhen
    Zhang, Miao
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] A CD276-Targeted Antibody-Drug Conjugate to Treat Non-Small Lung Cancer (NSCLC)
    Zhang, Jiashuai
    Zhou, Zhuoxin
    Chen, Kai
    Kim, Seulhee
    Cho, Irene Soohyun
    Varadkar, Tanvi
    Baker, Hailey
    Cho, Ju Hwan
    Zhou, Lufang
    Liu, Xiaoguang
    CELLS, 2023, 12 (19)
  • [3] Evaluating the potential of radiomics features to predict outcome to an antibody-drug conjugate therapy in non-small cell lung cancer patients
    Chen, Andrew W.
    Brady, Lauren K.
    Cohen, Eric A.
    Mankowski, Walter C.
    Roshkovan, Leonid
    Qutaish, Mohammed
    Katz, Sharyn
    Castro, Patricia G.
    Pencheva, Nora
    Jure-Kunkel, Maria
    Higgs, Brandon W.
    Kontos, Despina
    CANCER RESEARCH, 2024, 84 (06)
  • [4] Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither?
    Desai, Aakash
    Subbiah, Vivek
    Roy-Chowdhuri, Sinchita
    Sheshadri, Ajay
    Deshmukh, Sameer
    Peters, Solange
    CANCERS, 2024, 16 (22)
  • [5] Antibody-drug conjugates for non-small cell lung cancer: Advantages and challenges in clinical translation
    Zhao, Chenyu
    Zhang, Ruihan
    Yang, Huazhe
    Gao, Yiwei
    Zou, Ying
    Zhang, Xudong
    BIOCHEMICAL PHARMACOLOGY, 2024, 226
  • [6] Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: Emergence of a Novel Therapeutic Class
    Marks, Jennifer A.
    Wilgucki, Molly
    Liu, Stephen V.
    Reuss, Joshua E.
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1829 - 1841
  • [7] Antibody-Drug Conjugates in Non-Small Cell Lung Cancer: State of the Art and Future Perspectives
    Zanchetta, Carol
    De Marchi, Lorenzo
    Macerelli, Marianna
    Pelizzari, Giacomo
    Costa, Jacopo
    Aprile, Giuseppe
    Cortiula, Francesco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (01)
  • [8] Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers
    Khadela, Avinash
    Megha, Kaivalya
    Shah, Vraj B.
    Soni, Shruti
    Shah, Aayushi C.
    Mistry, Hetvi
    Bhatt, Shelly
    Merja, Manthan
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2024, 18
  • [9] TACSTD2 (Trop-2) constitutes a promising antibody-drug conjugate target for patients with non-small cell lung cancer brain metastases
    Hijazo-Pechero, S.
    Alay Badosa, A.
    Vilarino, N.
    Brenes Castro, J.
    Moliner, L.
    Mosteiro, M-A.
    Vidal, N.
    Munoz-Pinedo, C.
    Bruna, J.
    Nadal, E.
    ANNALS OF ONCOLOGY, 2023, 34
  • [10] Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
    Koopman, Louise A.
    Terp, Mikkel G.
    Zom, Gijs G.
    Janmaat, Maarten L.
    Jacobsen, Kirstine
    Gresnigt-van den Heuve, Elke
    Brandhorst, Marcel
    Forssmann, Ulf
    de Bree, Freddy
    Pencheva, Nora
    Lingnau, Andreas
    Zipeto, Maria A.
    Parren, Paul W. H., I
    Breij, Esther C. W.
    Ditzels, Henrik J.
    JCI INSIGHT, 2019, 4 (21)
12345